Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 16, Issue 4, 2014, Pages

  Rodgman, J C ^a,b   Verrico, Christopher D ^a   Worthy, Ray B ^c   Lewis, Erica E ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Michael E DeBakey VA   (United States)

^c River Oaks Hospital   (United States)

^d William Carey University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID DERIVATIVE; CLONIDINE; COCAINE; CYPROHEPTADINE; ESCITALOPRAM; METOCLOPRAMIDE; NALTREXONE; PHENOBARBITAL; TIZANIDINE;

ANXIETY; APPETITE; CASE REPORT; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MALNUTRITION; MOJO ADDICTION; NAUSEA; SCHOOL CHILD; SEIZURE; SYSTOLIC BLOOD PRESSURE; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 84944339284     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13l01594     Document Type: Letter

References (9)

1. Anderson E. Synthetic forms of marijuana outlawed in Louisiana. The Times Picayune [Newspaper]. http://www.nola.com/politics/index.ssf/2010/06/synthetic_forms_of_marijuana_o.html. Updated June 29, 2010. Accessed August 15, 2013.
2. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Results on Drug Use: 2012 Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan; 2013.
3. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525-540. PubMed doi:10.1007/s00213-013-3188-4.
4. DAWN. National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network; 2013.
5. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology. 2002;26(4):479-488.PubMed doi:10.1016/S0893-133X(01)00367-0.
6. Nacca N, Vatti D, Sullivan R, et al. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7(4):296-298. PubMed doi:10.1097/ADM.0b013e31828e1881.
7. Robledo P, Berrendero F, Ozaita A, et al. Advances in the field of cannabinoid: opioid cross-talk. Addict Biol. 2008;13(2):213-224. PubMed doi:10.1111/j.1369-1600.2008.00107.x.
8. Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl). 2010;211(2):141-148. PubMed doi:10.1007/s00213-010-1875-y.
9. Shoenfeld N, Bodnik D, Rosenberg O, et al. Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs [article in Hebrew]. Harefuah. 2011;150(12):888-892, 937. PubMed.